Abstract:INTRODUCTION AND OBJECTIVE: The PURE-01 and ABACUS studies has elucidated the administration of neoadjuvant immune checkpoint inhibitors in muscle-invasive bladder cancer (MIBC), with ef ﬁ cacy comparable to chemotherapy and less adverse events. However, the role of PD-1/PD-L1 inhibitor combining with chemotherapy remains unclear. We conduct a study to evaluate the outcome of pts treated with neoadjuvant PD-1 combined with second- line chemotherapy for MIBC. METHODS: TRUCE-01 is a phase II study of Tislelizumab combined with Nab-Paclitaxel before cystectomy or complete TURBT (cTURBT): the primary endpoint is pathologic complete response (pT0). Pts with clinical stage T2-4aN0-1M0 received tislelizumab 200mg on days 1 plus paclitaxel 200mg on days 2 every 3 weeks (Q3W) x 3 cycles followed by radical cystectomy or cTURBT. Biomarker analyses included programmed death-ligand 1 (PD-L1) expression using the combined positive score (CPS; Dako 22C3 pharmDx assay) and tumor mutational burden (TMB). Comparisons between PD-L1 expression subgroups were made via Fisher's exact tests for categorical variables. RESULTS: Between July 2020 and July 2021, 30 pts have completed neoadjuvant treatment and received radical cystectomy (n [ 9, 31%) or cTURBT (n [ 21, 69%). Finally, 16 pts achieved pT0 (53.3%; 95% CI, 36.7% to 73.3%). As a secondary end point, down- staging to pT < 2 was achieved in 21 pts (70%; 95% CI, 53.3% to 86.7%). There were 2 pts experienced grade 3-4 adverse events (CTCAE), a grade 3 rash and a grade 4 acute renal failure, both of them recovered after treating by corticosteroid. In addition, The most common grade 1-2 adverse events include alopecia (96%), fatigue (63%), hy-perglycemia (33%), rash (27%), fever (17%), and Creatinine increased (13%). There was no signi ﬁ cant correlation between PD-L1 expression and therapeutic effect. pT0 was achieved in 8 pts (61.5%) with PD-L1 positive compared with 8 pts (47%) with PD-L1 negative (P [ .484). As for tumor mutational burden (TMB), response pts show high lever (P [ .067). CONCLUSIONS: The early ef ﬁ cacy data further support the role of Tislelizumab combined with Paclitaxel as neoadjuvant therapy in MIBC, bene ﬁ ting them in a higher rate of pCR without increasing fre-quency of serve AEs. PD-L1 expression has no obvious correlation with the ef ﬁ cacy of immunotherapy combined chemotherapy. Patients with high TMB are more likely to respond to neoadjuvant therapy. Enrollment is ongoing. Source of Funding: The present study received ﬁ nancial from the the Science (grant prognosis for patients undergoing RC. patients with prospectively assessed baseline HRQOL prior RC were included. were strati ed by the global health status (GHS) domain of the EORTC QLQ-C30 questionnaire, and good general HRQOL was de ﬁ ned as GHS (cid:4) 70 based on validated cut-off levels. A 1:2 propensity-score-matched analysis of n [ 357 patients [n [ 125 (GHS (cid:4) 70), n [ 232 (GHS < 70)] was performed. Primary endpoint was cancer-speci ﬁ c survival (CSS), secondary endpoints encompassed overall survival (OS) and recurrence-free survival (RFS). Multivariate Cox regression models were performed to assess prognostic signi ﬁ cance of baseline GHS on survival outcomes.RESULTS: Median follow-up was 40.5mo. Patients subcohorts well-balanced. All baseline QLQ-C30 functioning were in favour of the GHS (cid:4) 70 cohort (each p < 0.001). 5-yr CSS (82% vs. 65%; p [ 0.001), 5-yr OS (76% vs 53%; p [ 0.001) and 5-yr-RFS (50% vs. 39%; p [ 0.04) and were signi ﬁ cantly increased in the GHS (cid:4) 70 cohort. GHS (cid:4) 70 was con ﬁ rmed as an independent predictor for increased CSS (HR 0.43, 95%CI 0.21 e 0.89; p [ 0.028), OS (HR 0.56, 95%CI 0.31 e 0.90; p [ 0.031) and RFS (HR 0.52, 95% CI 0.31 e 0.87; p [ 0.013) multivariate analysis. intent for bladder cancer. We found baseline good general HRQOL to accurately predict increased CSS, OS and RFS. We explored and analyzed the transcriptomic gene expression of cancer patient datasets consisting of non-muscle (NMIBC) and muscle invasive subtype (MIBC) from NCBI GEO (GSE154261, GSE57813, and GSE37317). The datasets were analyzed using GEO2R and Limma R packages. Pathway enrichment analysis of differentially expressed genes (DEGs) and between the NMIBC and MIBC group were analyzed by using the ingenuity pathway analysis (IPA), metascape web based portal and cytoscape. (metastatic phenotype) with the relative UROsta (benign) urothelial total of 1516 DEGs were identi ﬁ ed between non-muscle and muscle invasive bladder cancer specimens. To identify genes of prognostic value, we performed Gene Ontology (GO) and Kyoto Gene and Genomic encyclopedia (KEGG) analysis. A total of CDKN2A , , CTSV , , , KRT23 S100A9 rmed strong prognostic values in validated qRT-PCR in various human cancer cells representing stage-speci ﬁ c disease progression. protein ﬁ the of 3-panel predict the progression and prognosis of bladder cancer. P < 0.001) and body mass index of < 23.4 (OR [ 8.7; 95% CI [ 1.9-39.7; P [ 0.005) were independent predict factors for poor acquisition of skills for stoma management. CONCLUSIONS: The Mini-Cog test is a useful tool that predicts preoperatively which patients will not be able to manage their stoma independently. OBJECTIVE: RESECT is an interna- tional multicentre observational study of transurethral resection of bladder tumour (TURBT) surgery. TURBT practice has been shown to be associated with oncological outcomes. The aim of this analysis was to measure the global achievement of 4 TURBT quality indicators (QI) and determine if there is need for improvement. METHODS: Patients included were consecutive, primary ( ﬁ rst) tumour TURBT cases undertaken with curative intent. QIs and eligibility criteria were set a priori with consensus from an expert panel and in-vestigators were blinded to this. These were: Detrusor muscle sampled (QI1-DM þ ) (eligible: tumours > 5mm); Single instillation intravesical chemotherapy given within 24

VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT

Photodynamic diagnosis‐assisted transurethral resection of bladder tumor for high‐risk non‐muscle invasive bladder cancer improves intravesical recurrence‐free survival (BRIGHT study)

Differences in oncological benefits from second transurethral resection between white‐light initial surgery and photodynamic diagnosis‐guided initial surgery for primary high‐risk non‐muscle invasive bladder cancer

Role of Repeat Transurethral Resection in No-Muscle-invasive Bladder Tumour: an Umbrella Review

PIVOT-006: A phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT).

Efficacy and safety of a novel 450 nm blue diode laser versus plasmakinetic electrocautery for the transurethral resection of non-muscle invasive bladder cancer: The protocol and result of a multicenter randomized controlled trial

The HELENA study: Hexvix®-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study

Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer

An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial

Efficacy and Safety of Transurethral Resection of Bladder Tumour Combined with Chemotherapy and Immunotherapy in Bladder-Sparing Therapy in Patients with T1 High-Grade or T2 Bladder Cancer: a Protocol for a Randomized Controlled Trial.

Randomized controlled study of photoselective en bloc transurethral resection of non-muscle invasive bladder tumor with green laser

Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)

Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial

Prospective Observational Study and Analysis of Radiologist Learning Curve

Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial

PD10-07 UPDATE OF TRUCE-01: NEOADJUVANT TISLELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA

Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).

A retrospective comparison of thulium laser en bloc resection of bladder tumor and plasmakinetic transurethral resection of bladder tumor in primary non-muscle invasive bladder cancer